vs
Side-by-side financial comparison of Madison Square Garden Sports Corp. (MSGS) and Bio-Techne (TECH). Click either name above to swap in a different company.
Madison Square Garden Sports Corp. is the larger business by last-quarter revenue ($403.4M vs $295.9M, roughly 1.4× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 2.0%, a 10.8% gap on every dollar of revenue. On growth, Madison Square Garden Sports Corp. posted the faster year-over-year revenue change (12.8% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -3.1%).
Madison Square Garden Sports Corp. is an American sports holding company based in New York City.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
MSGS vs TECH — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $403.4M | $295.9M |
| Net Profit | $8.2M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 5.5% | 18.4% |
| Net Margin | 2.0% | 12.8% |
| Revenue YoY | 12.8% | -6.4% |
| Net Profit YoY | 641.9% | 68.3% |
| EPS (diluted) | $0.34 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $403.4M | $295.9M | ||
| Q3 25 | $39.5M | — | ||
| Q2 25 | $204.0M | $317.0M | ||
| Q1 25 | $424.2M | $316.2M | ||
| Q4 24 | $357.8M | $297.0M | ||
| Q3 24 | $53.3M | $289.5M | ||
| Q2 24 | $227.3M | $306.1M | ||
| Q1 24 | $430.0M | $303.4M |
| Q4 25 | $8.2M | $38.0M | ||
| Q3 25 | $-8.8M | — | ||
| Q2 25 | $-1.8M | $-17.7M | ||
| Q1 25 | $-14.2M | $22.6M | ||
| Q4 24 | $1.1M | $34.9M | ||
| Q3 24 | $-7.5M | $33.6M | ||
| Q2 24 | $25.5M | $40.6M | ||
| Q1 24 | $37.9M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 5.5% | 18.4% | ||
| Q3 25 | -69.5% | — | ||
| Q2 25 | -11.1% | -7.5% | ||
| Q1 25 | 7.6% | 12.2% | ||
| Q4 24 | 3.7% | 16.0% | ||
| Q3 24 | -15.5% | 13.8% | ||
| Q2 24 | 23.0% | 15.0% | ||
| Q1 24 | 18.5% | 22.1% |
| Q4 25 | 2.0% | 12.8% | ||
| Q3 25 | -22.3% | — | ||
| Q2 25 | -0.9% | -5.6% | ||
| Q1 25 | -3.4% | 7.1% | ||
| Q4 24 | 0.3% | 11.7% | ||
| Q3 24 | -14.1% | 11.6% | ||
| Q2 24 | 11.2% | 13.3% | ||
| Q1 24 | 8.8% | 16.2% |
| Q4 25 | $0.34 | $0.24 | ||
| Q3 25 | $-0.37 | — | ||
| Q2 25 | $-0.08 | $-0.11 | ||
| Q1 25 | $-0.59 | $0.14 | ||
| Q4 24 | $0.05 | $0.22 | ||
| Q3 24 | $-0.31 | $0.21 | ||
| Q2 24 | $1.07 | $0.26 | ||
| Q1 24 | $1.57 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $81.3M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $-282.1M | $2.0B |
| Total Assets | $1.5B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $81.3M | $172.9M | ||
| Q3 25 | $48.6M | — | ||
| Q2 25 | $144.6M | $162.2M | ||
| Q1 25 | $96.5M | $140.7M | ||
| Q4 24 | $107.8M | $177.5M | ||
| Q3 24 | $52.3M | $187.5M | ||
| Q2 24 | $89.1M | $152.9M | ||
| Q1 24 | $40.0M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $-282.1M | $2.0B | ||
| Q3 25 | $-294.2M | — | ||
| Q2 25 | $-281.4M | $1.9B | ||
| Q1 25 | $-283.4M | $2.0B | ||
| Q4 24 | $-273.1M | $2.1B | ||
| Q3 24 | $-277.5M | $2.1B | ||
| Q2 24 | $-266.3M | $2.1B | ||
| Q1 24 | $-294.0M | $2.0B |
| Q4 25 | $1.5B | $2.5B | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.5B | $2.6B | ||
| Q4 24 | $1.4B | $2.7B | ||
| Q3 24 | $1.4B | $2.7B | ||
| Q2 24 | $1.3B | $2.7B | ||
| Q1 24 | $1.4B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.4M | — |
| Free Cash FlowOCF − Capex | $31.6M | — |
| FCF MarginFCF / Revenue | 7.8% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 3.94× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-480.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.4M | — | ||
| Q3 25 | $-85.0M | — | ||
| Q2 25 | $49.7M | $98.2M | ||
| Q1 25 | $6.3M | $41.1M | ||
| Q4 24 | $61.8M | $84.3M | ||
| Q3 24 | $-26.2M | $63.9M | ||
| Q2 24 | $108.4M | $75.5M | ||
| Q1 24 | $4.0M | $81.0M |
| Q4 25 | $31.6M | — | ||
| Q3 25 | $-85.3M | — | ||
| Q2 25 | $49.4M | $93.3M | ||
| Q1 25 | $3.9M | $31.0M | ||
| Q4 24 | $61.2M | $77.5M | ||
| Q3 24 | $-26.5M | $54.7M | ||
| Q2 24 | $108.0M | $57.5M | ||
| Q1 24 | $3.9M | $64.5M |
| Q4 25 | 7.8% | — | ||
| Q3 25 | -216.3% | — | ||
| Q2 25 | 24.2% | 29.4% | ||
| Q1 25 | 0.9% | 9.8% | ||
| Q4 24 | 17.1% | 26.1% | ||
| Q3 24 | -49.7% | 18.9% | ||
| Q2 24 | 47.5% | 18.8% | ||
| Q1 24 | 0.9% | 21.3% |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.6% | 3.2% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.7% | 3.2% | ||
| Q2 24 | 0.2% | 5.9% | ||
| Q1 24 | 0.0% | 5.4% |
| Q4 25 | 3.94× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | 55.61× | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | 4.25× | 1.86× | ||
| Q1 24 | 0.11× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MSGS
| Event Related | $167.2M | 41% |
| Media Rights | $122.3M | 30% |
| Sponsorship Signage And Suite Licenses | $98.5M | 24% |
| League Distribution | $15.4M | 4% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
